Central venous catheter occlusion and thrombosis

Critical Care Clinics

Volumn 19, Issue 3, 2003, Pages 489-514

  Jacobs, Brian R ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NITRIC OXIDE; NITROVASODILATOR AGENT; PROSTACYCLIN; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANTICOAGULANT THERAPY; BLOOD VESSEL INJURY; CATHETER; CATHETER OCCLUSION; CENTRAL VENOUS CATHETER; CENTRAL VENOUS CATHETER OCCLUSION; CLINICAL TRIAL; CONTINUOUS INFUSION; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; DISSEMINATED INTRAVASCULAR CLOTTING; EMBOLISM; ENDOCARDIAL THROMBOSIS; FIBRIN SHEATH; HEPARINIZATION; HUMAN; HYPOTHROMBOGENIC CATHETER; INFECTION; INTERMITTENT THROMBOLYTIC THERAPY; INTERVENTIONAL RADIOLOGY; MECHANICAL OBSTRUCTION; MORBIDITY; MORTALITY; ORAL ANTICOAGULATION THERAPY; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBECTOMY; THROMBOLYTIC CONTINUOUS INFUSION THERAPY; THROMBOSIS; VENA CAVA FILTER; VENOUS STASIS;

EID: 0037969587     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(03)00002-2     Document Type: Review

References (125)

1. Kanter RK, Zimmerman JJ, Strauss RH, et al. Central venous catheter insertion by femoral vein: safety and effectiveness for the pediatric patient. Pediatrics 1986;77:842-7.
2. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000;132:391-402.
3. Nuss R, Hays T, Manco-Johnson M. Childhood thrombosis. Pediatrics 1995;96:291-4.
4. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analysis of the Canadian registry of VTE. Blood 1994;83:1251-7.
5. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995;96:939-43.
6. Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusion? J Parenter Enteral Nutr 1995;19:75-9.
7. Bozzetti F, Scarpa D, Terno G, et al. Subclavian venous thrombosis due to indwelling catheters: a prospective study on 52 patients. J Parenter Enteral Nutr 1983;7(6):560-2.
8. Holcombe BJ, Forloines-Lynn S, et al. Restoring patency of long-term central venous access devices. J Intraven Nurs 1992;15:36-41.
9. ter Borg F, Timmer J, de Kam SS, et al. Use of sodium hydroxide solution to clear partially occluded vascular access ports. J Parenter Enteral Nutr 1993;17:289-91.
10. Akinwande KI, Keehn DM. Dissolution of phenytoin precipitate with sodium bicarbonate in an occluded central venous access device. Ann Pharmacother 1995;29:707-9.
11. Breaux Jr. CW, Duke D, Georgeson KE, et al. Calcium phosphate crystal occlusion of central venous catheters used for total parenteral nutrition in infants and children: prevention and treatment. J Pediatr Surg 1987;22:829-32.
12. Flurkey H. A case presentation: precipitate in the central venous line: what went wrong? Neonatal Netw 1994;13:51-5.
13. Pennington CR, Pithie AD. Ethanol lock in the management of catheter occlusion. J Parenter Enteral Nutr 1987;11:507-8.
14. Tschirhart JM, Rao MK. Mechanism and management of persistent withdrawal occlusion. Am Surg 1988;54:326-8.
15. Young C, Gould JR. The timing and sequence of multiple device-related complications in patients with indwelling subcutaneous ports. Am J Surg 1997;174:417-21.
16. Hinke DH, Zandt-Stastny DA, Goodman LR, et al. Pinch-off syndrome: a complication of implantable subclavian venous access devices. Radiology 1990;177:353-6.
17. Hoshal VL, Ause RG, Hoskins PA. Fibrin sleeve formation on indwelling subclavian central venous catheters. Arch Surg 1971;102:353-7.
18. Berman Jr. W, Fripp RR, Yabek SM, et al. Great vein and right atrial thrombosis in critically ill infants and children with central venous lines. Chest 1991;99:963-7.
19. Lowell JA, Bothe Jr. A. Central venous catheter related thrombosis. Surg Oncol Clin N Am 1995;4:479-92.
20. Stump DC, Mann KG. Mechanisms of thrombus formation and lysis. Ann Emerg Med 1988;17:1138-47.
21. Tang L, Eaton JW. Fibrin(ogen) mediates acute inflammatory responses to biomaterials. J Exp Med 1993;178:2147-56.
22. Glaser DW, Medeiros D, Rollins N, et al. Catheter-related thrombosis in children with cancer. J Pediatr 2001;138:255-9.
23. Sharma A, Zilleruelo G, Abitbol C, et al. Survival and complications of cuffed catheters in children on chronic hemodialysis. Pediatr Nephrol 1999;13:245-8.
24. Libsack CV, Kollmeyer KR. Role of catheter surface morphology on intravascular thrombosis of plastic catheters. J Biomed Mater Res 1979;13:459-66.
25. Borow M, Crowley JG. Evaluation of central venous catheter thrombogenicity. Acta Anaesth Scand 1985;81:59-64.
26. Ross AH, Griffith CD, Anderson JR, et al. Thromboembolic complications with silicone elastomer subclavian catheters. J Parenter Enteral Nutr 1982;6:61-3.
27. Nowak-Göttl U, Dübbers A, Kececioglu D, et al. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study. J Pediatr 1997;131:608-12.
28. Hagstrom JN, Walter J, Bluebond-Langner R, et al. Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease. J Pediatr 1998;133:777-81.
29. Lindqvist PG, Olofsson P, Dahlback B. Use of selective factor V Leiden screening in pregnancy to identify candidates for anticoagulants. Obstet Gynecol 2002;100:332-6.
30. Beck C, Dubois J, Grignon A, et al. Incidence and risk factors of catheter-related deep vein thrombosis in a pediatric intensive care unit: a prospective study. J Pediatr 1998;133:237-41.
31. Massicotte MP, Dix D, Monagle P, et al. Central venous catheter related thrombosis in children: analysis of the Canadian registry of venous thromboembolic complications. J Pediatr 1998;133:770-6.
32. Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995;74:415-25.
33. Donnelly KM. Venous thromboembolic disease in the pediatric intensive care unit. Curr Opin Pediatr 1999;11:213-7.
34. Wakefield A, Cohen Z, Craig M, et al. Thrombogenicity of total parenteral nutrition solutions: I. Effect on induction of monocyte/macrophage procoagulant activity. Gastroenterology 1989;97:1210-28.
35. Dollery CM, Sullivan ID, Bauraind O, et al. Thrombosis and embolism in long-term central venous access for parenteral nutrition. Lancet 1994;344:1043-5.
36. Korones DN, Buzzard CJ, Asselin BL, et al. Right atrial thrombi in children with cancer and indwelling catheters. J Pediatr 1996;128:841-6.
37. Krafte-Jacobs B, Sivit CJ, Mejia R, et al. Catheter related thrombosis in critically ill children: comparison of heparin and non-heparin bonded catheters. J Pediatr 1995;126:50-4.
38. Talbott GA, Winters WD, Bratton SL, et al. A prospective study of femoral catheter-related thrombosis in children. Arch Pediatr Adolesc Med 1995;149:288-91.
39. Rockoff MA, Gang DL, Vacanti JP. Fatal pulmonary embolism following removal of a central venous catheter. J Pediatr Surg 1984;19:307-9.
40. Derish MT, Smith DW, Frankel LR. Venous catheter thrombus formation and pulmonary embolism in children. Pediatr Pulmonol 1995;20:349-54.
41. Bonnet F, Loriferne JF, Texier JP, et al. Evaluation of Doppler examination for diagnosis of catheter-related deep vein thrombosis. Intensive Care Med 1989;50:687-9.
42. Koksoy C, Kuzu A, Kutlay J, et al. The diagnostic value of colour Doppler ultrasound in central venous catheter related thrombosis. Clin Radiol 1995;50:687-9.
43. Haire WD, Lynch TG, Lieberman RP, et al. Utility of duplex ultrasound in the diagnosis of asymptomatic catheter-induced subclavian vein thrombosis. J Ultrasound Med 1991;10:493-6.
44. Barnes C, Newall F, Monagle P. Post-thrombotic syndrome. Arch Dis Child 2002;86:212-4.
45. Brandies DPM, Buller HR, Heiiboer H, et al. Randomized trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997;349:759-62.
46. Raad II, Luna M, Khalil SA. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994;271:1014-6.
47. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risk factors, and relationship with catheter-related sepsis. Chest 1998;114:207-13.
48. Jurado R, Ribeiro M. Possible role of systemic inflammatory reaction in vascular access thrombosis. South Med J 1999;92:877-81.
49. Baumgartner JN, Cooper SL. Bacterial adhesion on polyurethane surfaces conditioned with thrombus components. ASAIO J 1996;42:M476-9.
50. Vaudaux PE, Pittet D, Haeberli A, et al. Host factors selectively increase staphylococcal adherence on inserted catheters: a role for fibronectin and fibrinogen or fibrin. J Infect Dis 1989;160:865-75.
51. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med 2000;26:967-72.
52. Fishbein JD, Friedman HS, Bennett BB, et al. Catheter-related sepsis refractory to antibiotics treated successfully with adjunctive urokinase infusion. Pediatr Infect Dis J 1990;9:676-8.
53. Kooij JD, van der Zant FM, van Beek EJ, et al. Pulmonary embolism in deep venous thrombosis of the upper extremity: more often in catheter-related thrombosis. Neth J Med 1997;50:238-42.
54. Horattas MC, Wright DJ, Fenton AH, et al. Changing concepts of deep venous thrombosis of the upper extremity-report of a series and review of the literature. Surgery 1988;104:561-7.
55. Monreal M, Lafoz E, Ruiz J, et al. Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest 1991;99:280-3.
56. Byard RW, Cutz E. Sudden and unexpected death in infancy and childhood due to pulmonary thromboembolism. An autopsy study. Arch Pathol Lab Med 1990;114:142-4.
57. Hoar PF, Wilson RM, Mangano DT, et al. Heparin bonding reduces thrombogenicity of pulmonary-artery catheters. N Engl J Med 1981;305:993-5.
58. Laster JL, Nichols WK, Silver D. Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies. Arch Intern Med 1989;149:2285-7.
59. Foley PL, Barthel CH, Brausa HR. Effect of covalently bound heparin coating on patency and biocompatibility of long-term indwelling catheters in the rat jugular vein. Comp Med 2002;52:243-8.
60. Francois P, Vaudaux P, Nurdin N, et al. Physical and biological effects of a surface coating procedure on polyurethane catheters. Biomaterials 1996;17:667-78.
61. Valk WJ, Liem KD, Geven WB. Seldinger technique as an alternative approach for percutaneous insertion of hydrophilic polyurethane central venous catheters in newborns. J Parenter Enteral Nutr 1995;19:151-5.
62. Randolph AG, Cook DJ, Gonzales CA, et al. Benefit of heparin in central venous and pulmonary artery catheters. A meta-analysis of randomized controlled trials. Chest 1998;113:165-71.
63. Fabri PJ, Mirtallo JM, Ruberg RL, et al. Incidence and prevention of thrombosis of the subclavian vein during total parenteral nutrition. Surg Gynecol Obstet 1982;155:238-40.
64. Brismar B, Hardstedt C, Jacobson S, et al. Reduction of catheter-associated thrombosis in parenteral nutrition by intravenous heparin therapy. Arch Surg 1982;117:1196-9.
65. Smith S, Dawson S, Hennessey R, et al. Maintenance of the patency of indwelling central venous catheters: is heparin necessary? Am J Pediatr Hematol Oncol 1991;13:141-3.
66. Chastre J, Cornud F, Bouchama A, et al. Thrombosis as a complication of pulmonary-artery catheterization via the internal jugular vein: prospective evaluation by phlebography. N Engl J Med 1982;306:278-81.
67. Ruggiero RP, Aisenstein TJ. Central catheter fibrin sleeve-heparin effect. J Parenter Enteral Nutr 1983;7:270-3.
68. Heeger PS, Backstrom JT. Heparin flushes and thrombocytopenia. Ann Intern Med 1986;105:143.
69. Garrelts JC. White clot syndrome and thrombocytopenia: reasons to abandon heparin i.v. lock flush solution. Clin Pharm 1992;11:797-9.
70. Potter C, Cox Gill J, Scott P, et al. Heparin-induced thrombocytopenia in a child. J Pediatr 1992;121:135-8.
71. Warkentin TE, Levine MN, Hirsc J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
72. Kalmanti M, Germanakis J, Stiakaki E, et al. Prophylaxis with urokinase in pediatric oncology patients with central venous catheters. Pediatr Hematol Oncol 2002;19:173-9.
73. Ray Jr. CE, Shenoy SS, McCarthy PL, et al. Weekly prophylactic urokinase instillation in tunneled central venous access devices. J Vasc Interv Radiol 1999;10:1330-4.
74. Henrickson KJ, Axtell RA, Hoover SM, et al. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial. J Clin Oncol 2000;18:1269-78.
75. Hentschel R, Wiescholek U, von Lengerke J, et al. Coagulation-associated complications of indwelling arterial and central venous catheters during heparin prophylaxis - a prospective study. Eur J Pediatr 1999;158:S126-9.
76. Randolph AG, Cook DJ, Gonzales CA, et al. Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials. BMJ 1998;316:969-75.
77. Shah P, Shah V. Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. Cochrane Database Syst Rev 2001;(3):CD002772.
78. Zobel G, Trop M, Muntean W, et al. Anticoagulation for continuous arteriovenous hemofiltration in children. Blood Purif 1988;6:90-5.
79. Jacobs BR, Barr L, Brilli R, et al. Intracatheter nitroglycerin infusion fails to prevent catheter-related venous thrombosis: a randomized, controlled trial. Intensive Care Med 2001;27:187-92.
80. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112:423-8.
81. Boraks P, Seale J, Price J, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 1998;101:483-6.
82. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J 2002;32:84-8.
83. Norwood SH, McAuley CE, Berne JD, et al. A potentially expanded role for enoxaparin in preventing venous thromboembolism in high risk blunt trauma patients. J Am Coll Surg 2001;192:161-7.
84. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000;136:439-45.
85. Steinhubl SR. Antiplatelet agents in cardiology: the choice of therapy. Ann Thorac Surg 2000;70:S3-8.
86. Kenney BD, David M, Bensoussan AL. Anticoagulation without catheter removal in children with catheter-related central vein thrombosis. J Pediatr Surg 1996;31:816-8.
87. Nazario R, Delorenzo LJ, Maguire AG. Treatment of venous thromboembolism. Cardiol Rev 2002;10:249-59.
88. Gal P, Ransom JL. Neonatal thrombosis: treatment with heparin and thrombolytics. DICP 1991;25:853-6.
89. Massicotte P, Julian JA, Gent K, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and Coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial [abstract]. Presented at the eighteenth International Society on Thrombosis and Haemostasis conference, July 6-12, 2001, Paris, France.
90. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular weight heparins compared to unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.
91. Haire WD, Atkinson JB, Stephens LC, et al. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost 1994;72:543-7.
92. Jacobs BR, Haygood M, Hingl J. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children. J Pediatr 2001;139:593-6.
93. Deitcher SR, Fesen MR, Kiproff PM, et al. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2002;20:317-24.
94. Haire WD, Lieberman RP, Lund GB, et al. Obstructed central venous catheters. Restoring function with a 12-hour infusion of low-dose urokinase. Cancer 1990;66:2279-85.
95. Haire WD, Lieberman RP. Thrombosed central venous catheters: restoring function with 6-hour urokinase infusion after failure of bolus urokinase. J Parenter Enteral Nutr 1992;16:129-32.
96. Whigham CJ, Greenbaum MC, Fisher RG, et al. Incidence and management of catheter occlusion in implantable arm ports: results in 391 patients. J Vasc Interv Radiol 1999;10:767-74.
97. Hartnell GG, Gates J. The case of Abbokinase and the FDA: the events leading to the suspension of Abbokinase supplies in the United States. J Vasc Interv Radiol 2000;11:841-7.
98. Tisdale JE, Colucci RD, Ujhelyi MR, et al. Evaluation and comparison of the adverse effects of streptokinase and alteplase. Pharmacotherapy 1992;12:440-4.
99. Rodenhuis S, van't Hek LG, Vlasveld LT, et al. Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator. Thorax 1993;48:558-9.
100. Bagnall HA, Gomperts E, Atkinson JB. Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis in infants and children. Pediatrics 1989;83:963-6.
101. Dillon PW, Fox PS, Berg CJ, et al. Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapy. J Pediatr Surg 1993;28:1264-8.
102. Knofler R, Dinger J, Kabus M, et al. Thrombolytic therapy in children-clinical experiences with recombinant tissue-plasminogen activator. Semin Thromb Hemost 2001;27:169-74.
103. Stock KW, Jacob AL, Schnabel KJ, et al. Massive pulmonary embolism: treatment with thrombus fragmentation and local fibrinolysis with recombinant human-tissue plasminogen activator. Cardiovasc Intervent Radiol 1997;20:364-8.
104. Ross Jr. P, Ehrenkranz R, Kleinman CS, et al. Thrombus associated with central venous catheters in infants and children. J Pediatr Surg 1989;24:253-6.
105. Hartmann J, Hussein A, Trowitzsch E, et al. Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature. Arch Dis Child Fetal Neonatal Ed 2001;85:F18-22.
106. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-5.
107. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-7.
108. Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 1999;94:3007-14.
109. Athanasoulis CA, Kaufman JA, Halpern EF, et al. Inferior vena caval filters: review of a 26-year single-center clinical experience. Radiology 2000;216:54-66.
110. Cahn MD, Rohrer MJ, Martella MB, et al. Long-term follow-up of Greenfield inferior vena cava filter placement in children. J Vasc Surg 2001;34:820-5.
111. Wacker P, Oberhansli I, Didier D, et al. Right atrial thrombosis associated with central venous catheters in children with cancer. Med Pediatr Oncol 1994;22:53-7.
112. Zana K, Otal P, Fornet B, et al. In vitro evaluation of a new rotational thrombectomy device: the Straub Rotarex catheter. Cardiovasc Intervent Radiol 2001;24:319-23.
113. Mewissen MW. Catheter-directed thrombolysis for lower extremity deep vein thrombosis. Tech Vasc Interv Radiol 2001;4:111-4.
114. Andrew M, Marzinotto V, Pencharz P, et al. A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. J Pediatr 1995;126:358-63.
115. Klement P, Du YJ, Berry L, et al. Blood-compatible biomaterials by surface coating with a novel antithrombin-heparin covalent complex. Biomaterials 2002;23:527-35.
116. Kishida A, Akatsuka Y, Yanagi M, et al. In vivo and ex vivo evaluation of the antithrombogenicity of human thrombomodulin immobilized biomaterials. ASAIO J 1995;41:M369-74.
117. Wang ZG, Zhang H, Pu LQ, et al. Can endothelial seeding enhance patency and inhibit neointimal hyperplasia?/pages/pages/pages/pages Experimental studies and clinical trial of endothelial seeded venous prostheses. Int Angiol 2000;19:259-69.
118. Lev EI, Marmur JD, Zdravkovic M, et al. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study. Arterioscler Thromb Vasc Biol 2002;22:1036-41.
119. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-40.
120. Palmerini T, Nedelman MA, Scudder LE, et al. Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates. J Am Coll Cardiol 2002;40:360-6.
121. Mousa SA. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr Opin Chem Biol 2002;6:534-41.
122. Kamishirado H, Inoue T, Mizoguchi K, et al. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J 2002;144:303-8.
123. st century. Arch Surg 2002;137:854-61.
124. Shefler A, Gillis J, Lam A, et al. Inferior vena cava thrombosis as a complication of femoral vein catheterisation. Arch Dis Child 1995;72:343-5.
125. Moore RA, McNicholas KW, Naidech H, et al. Clinically silent venous thrombosis following internal and external jugular central venous cannulation in pediatric cardiac patients. Anesthesiology 1985;62:640-3.